You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 4643 results
  1. Boron-containing antimalarial drug discovery

    SBC: REACTIVE BIOSCIENCES INC            Topic: NIAID

    PROJECT SUMMARY New drugs to treat malaria, ideally with unique chemical structures and mechanisms of action, are urgently needed. Optimal drug candidates for the treatment and prevention of malaria will have potent activity against cultured parasites and in animal models of malaria, be rapidly active against erythrocytic malaria parasites, be orally bioavailable, have extended pharmacological exp ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Dynamic Evaluation of Hypersonic Missile Debris Penetration

    SBC: CORVID TECHNOLOGIES, LLC            Topic: N161019

    Non-warhead debris from a typical anti-ship or air-to-air missile can comprise as much as 70% of the total striking mass, which makes it a crucial component of any lethality or survivability assessment and increasingly important as stand-off missile programs are rising in demand.  Many current LVS modeling tools in use by the government do not address residual non-warhead missile debris at all, a ...

    SBIR Phase II 2023 Department of DefenseDefense Advanced Research Projects Agency
  3. Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea

    SBC: AIMMAX THERAPEUTICS INC            Topic: NIAID

    PROJECT SUMMARY / ABSTRACT The CDC has identified Neisseria gonorrhoeae as a pathogen of the highest threat level (“Urgent Threat”) to the US public health. Currently there is only a single recommended agent remaining on the CDC treatment guidelines, an intramuscular injection of the extended spectrum cephalosporin, ceftriaxone. However, in the past decade, reports of resistance to ceftriaxone ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Commercializing CivaSheet for Pancreatic Cancer Patients

    SBC: CIVATECH ONCOLOGY INC            Topic: NCI

    CivaTech Oncology’s mission is to provide improved radiation therapy directly to diseased tissues while sparing healthy tissues. With NIH/NCI SBIR support, the Company has eliminated local recurrence of disease in pancreatic cancer patients – a huge success. Pancreatic cancer is predicted to soon become the most commonly diagnosed cancer in the US and there are no significant, impactful therap ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid and robust assay for measurement of in vivo activity of chromatin-interacting proteins

    SBC: Epicypher, Inc.            Topic: NIAID

    PROJECT SUMMARYThe activity of chromatin-associating proteins (CAPs) is fundamental to regulation of gene expression. Elucidating CAP activity is central to understanding the regulatory mechanisms that drive cell biology, both in the context of health and disease, and to guide development of novel therapeutics. However, this work is not straightforward, as CAP activity is regulated by multiple fac ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus

    SBC: Inhalon Biopharma Inc            Topic: NIAID

    Title: GMP manufacturing and IND Filing of IN-002, a potent inhaled “muco-trapping” antibody therapy for Respiratory Syncytial Virus Project Summary (30 line limit) Respiratory Syncytial Virus (RSV) is the leading cause of viral hospitalization and death in infants and young children and is also a major cause of respiratory illness in immune compromised adults and the elderly. Unfortunately, t ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959

    SBC: T3D Therapeutics, Inc.            Topic: NIA

    T3D-959 is a new chemical entity, orally delivered, small molecule, dual nuclear receptor agonist aimed at improving dysfunctional brain glucose energy and lipid metabolism in Alzheimer’s disease (AD), it is non- amyloid/non-tau-directed. Metabolic homeostasis, inherently altered in AD, leads to protein misfolding resulting in plaque formation, tangle formation and inflammation. Exploratory huma ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of ultra-efficient antibodies for single cell mapping applications

    SBC: Epicypher, Inc.            Topic: NIAID

    PROJECT SUMMARYHistone post-translational modifications (PTMs) are some of the most widely studied epigenomic factors, and alterations in histone PTM abundance / distribution have been implicated in numerous disease etiologies. Epigenomic mapping of histone PTMs in limited cell populations or single cells (SCs) would provide the opportunity to study the epigenetic landscape of rare and heterogenou ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development for ShockDefender against Hemorrhagic Shock

    SBC: ZYMERON CORP            Topic: DHA234D001

    Hemorrhagic shock is responsible for over 35% of prehospital traumatic deaths and over 40% of all deaths within the first 24 hours following injury. Multiple intervention strategies are necessary for prolonged prehospital management and improved casualty survivability including improved blood products, hemostatics, damage control resuscitation, as well as therapeutic interventions targeting coagul ...

    SBIR Phase II 2023 Department of DefenseDefense Health Agency
  10. Large Area Hard X-ray Imager Based on Metal Halide Perovskite Nanocrystals

    SBC: PEROTECH, INC.            Topic: HR001121S000721

    The current X-ray imaging devices ion the market cannot meet the rising requirements for more safe, higher resolution and portable X-ray imaging applications. One new technology, photon-counting X-ray detector, is revolutionizing the X-ray imaging process which afford high spatial resolution, almost zero electronic noise, much better signal-to-noise ratio, at orders of magnitude lower radiation do ...

    SBIR Phase II 2022 Department of DefenseDefense Advanced Research Projects Agency
US Flag An Official Website of the United States Government